Abstract:Hematopoietic cell kinase (Hck), a non-receptor tyrosine kinase belonging to the Src kinase family, is intricately linked to the pathogenesis of numerous human diseases, with a particularly pronounced association with cancer. Hck not only directly impacts the proliferation, migration, and apoptosis of cancer cells but also interacts with JAK/STAT, MEK/ERK, PI3K/AKT, CXCL12/CXCR4, and other pathways. Hck also influences the tumor microenvironment to facilitate the onset and progression of cancer. This paper delves into the functional role and regulatory mechanisms of Hck in various solid tumors. Additionally, it explores the implications of Hck in hematological malignancies. The review culminates with a summary of the current research status of Hck inhibitors, the majority of which are in the pre-clinical phase of investigation. Notably, these inhibitors are predominantly utilized in the therapeutic management of leukemia, with their combinatorial potential indicating promising avenues for future research. In conclusion, this review underscores the significance of the mechanism of Hck in solid tumors. This insight is crucial for comprehending the current research trends regarding Hck: targeted therapy against Hck shows great promise in both diagnosis and treatment of malignant tumors. Further investigation into the role of Hck in cancer, coupled with the development of specific inhibitors, has the potential to revolutionize approaches to cancer treatment.

Advances in the Research of JAK2 Abnormalities in Heamatological Disorders

[Inhibitors of JAK2/STAT Signaling Pathway and Hematologic Malignancies-Review].

Molecular basis of JAK2 H608Y and H608N mutations in the pathology of acute myeloid leukemia

Recent Progress in the Studies on Structure and Function of JAK2

[Progress of Study on JAK2V617F Mutation in Myeloproliferative Neoplasm].

The Effects of R683S (G) Genetic Mutations on the JAK2 Activity, Structure and Stability.

Effects of JAK2 V556F Mutation on the JAK2's Activity, Structural Stability and the Transformation of Ba/F3 Cells.

Roles of Germline JAK2 Activation Mutation JAK2 V625F in the Pathology of Myeloproliferative Neoplasms

Janus Kinase Signaling: Oncogenic Criminal of Lymphoid Cancers

Roles of T875N Somatic Mutation in the Activity, Structural Stability of JAK2 and the Transformation of OCI-AML3 Cells.

Disruption of R867 and Y613 Interaction Plays Key Roles in JAK2 R867Q Mutation Caused Acute Leukemia.

Molecular basis of JAK2 activation in erythropoietin receptor and pathogenic JAK2 signaling

JAK/STAT in leukemia: a clinical update

The Associations of Janus Kinase-2 (jak2) A830g Polymorphism and the Treatment Outcomes in Patients with Acute Myeloid Leukemia

Activating JAK2 mutants reveal cytokine receptor coupling differences that impact outcomes in myeloproliferative neoplasm

[Research Progress on Gene Mutation of Jak2].

Research of gene mutation in acute myeloid leukemia: development and prospect

Research Progress of Myeloproliferative Disorders: Several Clinical Problems Post the JAK2 Mutation Era

JAK2 inhibitors for the treatment of Philadelphia-negative myeloproliferative neoplasms: current status and future directions

Research progress of JAK1/2 inhibitors in the treatment of myeloproliferative neoplasms

Recent advances in hematopoietic cell kinase in cancer progression: Mechanisms and inhibitors